SciSparc Ltd., a specialty clinical-stage pharmaceutical company, announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays (Polyrizon).
As part of the collaboration, the two companies will work to develop a unique technology for the treatment of pain, based on SciSparc's SCI-160 platform and Polyrizon
